DOCSLIB.ORG

Effects of Alpha-2 Blockade on Sexual Response: Experimental Studies with Delequamine (RS15385)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effects of Alpha-2 Blockade on Sexual Response: Experimental Studies with Delequamine (RS15385) International Journal of Impotence Research (2000) 12, Suppl 1, S64±S69 ß 2000 Macmillan Publishers Ltd All rights reserved 0955-9930/00 $15.00 www.nature.com/ijir CLINICAL RESEARCH Effects of alpha-2 blockade on sexual response: experimental studies with Delequamine (RS15385) J Bancroft1 1The Kinsey Institute, Indiana University, USA The role of alpha-2 receptors and alpha-2 antagonists in central and peripheral mechanisms of sexual response are discussed. It is concluded that the predominant role of the alpha-2 antagonist centrally is to increase arousal which in certain circumstances, is sexual. It is further concluded that the predominant role of the alpha-2 antagonist peripherally is to modulate (block) the norepinephrine (NE)-induced contractility in the smooth muscle of the penis. How the central arousal mechanisms are speci®cally linked to sexual response is not understood. Experimental studies with a selective alpha-2 antagonist, delequamine, are brie¯y reviewed and their complex results discussed. Evidence from sleep studies was consistent with delequamine having both central excitatory and inhibitory effects, dependent on dosage. The possibility that men with psychogenic erectile dysfunction might have increased central alpha-2 tone was considered. The apparent loss of responsiveness to the alpha-2 antagonist in older dysfunctional men was discussed. More questions are raised than answered; further research is needed in this area. International Journal of Impotence Research (2000) 12, Suppl 1, S64±S69 Keywords: alpha-2 blockade; delequamine Role of adrenergic agonists locus coeruleus (l.c.) and the lateral tegmental nucleus (l.t.n.).2 Each nucleus has neurons with ascending and descending projections. Of the two, The pharmacological agent with the longest history the l.c. system is most likely to be relevant to sexual for enhancing sexual response is yohimbine, origin- arousal and response; it is activated by novel 1 ally available as a plant (bark) extract. Yohimbine's sensory input to produce a state of central arousal principal pharmacological action is as an alpha-2 which may be associated with aversive or rewarding adrenoceptor antagonist. Activation of presynaptic situations. The ascending projections of the l.c. alpha-2 receptors increases re-uptake of norepi- terminate, quite widely, in the dorsal thalamus, nephrine (NE) at the synapse, hence reducing NE hypothalamus, basal forebrain, including hippocam- transmission. Antagonism of presynaptic alpha-2 pus, and the frontal cortex. The descending projec- receptors will therefore have the principal effect of tions from the l.c. go to the spinal cord (mainly increasing NE transmission. Antagonism of post- ventral horn) and to sensory nuclei in the brain synaptic alpha-2 receptors will inhibit NE action at stem. The l.c. neurons are populated with alpha-2 the smooth muscle. Both central and peripheral receptors.3 effects of such a drug need to be considered. Davidson's group showed that yohimbine and other alpha-2 antagonists such as idazoxan, could substantially restore sexual behavior in the castrated The role of the norepinephrine system male rat and that the sexually enhancing effect of yohimbine was independent of any direct effect on Central effects erection, leading them to conclude that the drug's principal effect was on central arousal.4 There are good reasons for expecting an alpha-2 antagonist to have central effects. The NE system in Peripheral effects the brain originates in two brain stem nuclei, the Some attention has been paid to the presence and Correspondence: Dr J Bancroft, The Kinsey Institute, possible function of alpha-2 receptors in the erectile 5 Morrison Hall 313, Bloomington, IN 46164. tissue. Saenz de Tejada et al concluded that Received 2 September 1999; accepted 15 November 1999 adrenergic activity is modulated, in part, by pre- Effects of alpha-2 blockade on sexual response J Bancroft S65 synaptic alpha-2 receptors in the corpus caverno- satiation or exhaustion in rats. This state, which sum; in those circumstances an alpha-2 antagonist results from repeated copulation, is characterized by would be expected to increase NE transmission and a prolonged period of sexual unresponsiveness, hence smooth muscle contractility. Andersson6 lasting for several days before recovery.13,14 This suggested that such alpha-2 receptor activity may unresponsive state can be partially corrected with a play an important role in the cavernous artery wall, variety of pharmacological manipulations including but not in the trabecular smooth muscle. However, the opioid antagonist, naloxone (indicating that Traish et al7 identi®ed post-synaptic alpha-2 recep- opioid inhibition is probably involved), 8-OH- tors on the trabecular smooth muscle, though the DPAT, a 5HT1a agonist (indicating that serotonergic function of these receptors remains unclear.8 The inhibition is involved), and yohimbine. However, very limited evidence of the effects of injecting the effects of the ®rst two require an intact NE alpha-2 antagonists into the corpus cavernosum system, indicating complex interactions between indicates very little effect.9 If a drug produces a peptide and catecholamine systems.15±17 predominantly presynaptic antagonistic effect on Thus, in those circumstances where central alpha-2 receptors in the erectile tissues, the con- arousal is elicited by an aversive situation, we sequence would be an increased release of NE and should not be surprised if this NE system produces a resulting increase in contractile tone. The central arousal of `anxiety' type and peripheral possibility of a post-synaptic effect of alpha-2 inhibition of sexual response at the same time. receptor antagonist on inhibition of NE binding on Conversely, when central arousal is in response to the trabecular smooth muscle has to be considered, sexual stimuli we might expect a reduced pre- with two such contrasting effects possibly cancel- synaptic peripheral inhibition of genital response, ling each other out. although there does not appear to be any evidence directly relevant to that point. The integrating component of the system is presumably the l.c., The relationship between the central and with both its upwards and downwards projections. peripheral effects of the NE system It may be relevant that of the two sources of neuronal input to the l.c., one of them is from the nucleus paragigantocellularis (nPGi) which has We thus have a paradox; central effects of NE on direct, serotonergically mediated inhibitory in¯u- sexual response are excitatory and presynaptic ences on the erectile response.18 peripheral effects are probably inhibitory. The ®rst In conclusion, whereas it is clear that the central fundamental point in tackling this paradox is to NE system is of fundamental importance to sexual recognize that the excitatory central effects of the NE arousal and response, we remain largely ignorant of system are not con®ned to sexual arousal. The how it functions in that respect. upward projections of the l.c. are involved in general arousal, and in many circumstances it is entirely appropriate that elicitation of general central arousal should require localized peripheral inhibition of genital response. Thus if the NE system generates `arousal' in response to the threat of Pharmacological studies in humans punishment, an emotional state which in those circumstances Gray10 would call `anxiety', then inhibition of other response patterns, such as sexual A series of clinical studies of the effect of yohimbine response, which might interfere with an appropriate in men with erectile dysfunction have been carried avoidance response would be adaptive. However, out.19±22 Most of these studies have been affected by one of the principal mysteries of the central NE methodological problems of various kinds, but a system is how it is mobilized to serve sexual consistent though weak average bene®cial effect on function in some situations and avoidance behavior erectile function has been reported, presumably due in others.11 Testosterone may be relevant to this to central effects of the drug. In experimental selective process, because of the capacity for alpha-2 studies, yohimbine induces anxiety23 and combined antagonists to restore sexual behavior in castrated with naloxone, it produces both anxiety and penile male rats (see above), though the mechanism of this erection.24 Anxiety has not been a problem as a side hormonal effect is far from clear. Further complexity effect in the treatment studies cited above, and it is suggested in a study by Sala et al,12 showing a remains a question of some interest why anxiety has curvi-linear dose response relationship between an been evoked in such experimental studies, but not alpha-2 antagonist and central excitation, with in treatment studies. It may be a matter of acute middle range doses producing maximal excitatory dosage contrasted with chronic dosage; or it may be effects and high doses inhibitory effects. dependent on the context in which the drug is The relevance of the central NE system to sexual taken. Given its theoretical importance, further arousal is further indicated from studies of sexual research should be directed at this issue. International Journal of Impotence Research Effects of alpha-2 blockade on sexual response J Bancroft S66 Experimental human studies with a speci®c alpha-2 Two types of experimental procedures were antagonist, Delequamine therefore used, both involving intravenous infusion of the drug in two contrasting dosages (`high'
Load more

Recommended publications
  • Emerging Evidence for a Central Epinephrine-Innervated A1- Adrenergic System That Regulates Behavioral Activation and Is Impaired in Depression
    Neuropsychopharmacology (2003) 28, 1387–1399 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Perspective Emerging Evidence for a Central Epinephrine-Innervated a1- Adrenergic System that Regulates Behavioral Activation and is Impaired in Depression ,1 1 1 1 1 Eric A Stone* , Yan Lin , Helen Rosengarten , H Kenneth Kramer and David Quartermain 1Departments of Psychiatry and Neurology, New York University School of Medicine, New York, NY, USA Currently, most basic and clinical research on depression is focused on either central serotonergic, noradrenergic, or dopaminergic neurotransmission as affected by various etiological and predisposing factors. Recent evidence suggests that there is another system that consists of a subset of brain a1B-adrenoceptors innervated primarily by brain epinephrine (EPI) that potentially modulates the above three monoamine systems in parallel and plays a critical role in depression. The present review covers the evidence for this system and includes findings that brain a -adrenoceptors are instrumental in behavioral activation, are located near the major monoamine cell groups 1 or target areas, receive EPI as their neurotransmitter, are impaired or inhibited in depressed patients or after stress in animal models, and a are restored by a number of antidepressants. This ‘EPI- 1 system’ may therefore represent a new target system for this disorder. Neuropsychopharmacology (2003) 28, 1387–1399, advance online publication, 18 June 2003; doi:10.1038/sj.npp.1300222 Keywords: a1-adrenoceptors; epinephrine; motor activity; depression; inactivity INTRODUCTION monoaminergic systems. This new system appears to be impaired during stress and depression and thus may Depressive illness is currently believed to result from represent a new target for this disorder.
    [Show full text]
  • Β2‑Adrenergic Receptor Functionality and Genotype in Two Different Models of Chronic Inflammatory Disease: Liver Cirrhosis and Osteoarthritis
    MOLECULAR MEDICINE REPORTS 17: 7987-7995, 2018 β2‑adrenergic receptor functionality and genotype in two different models of chronic inflammatory disease: Liver cirrhosis and osteoarthritis REYES ROCA1, PABLO ESTEBAN1, PEDRO ZAPATER2,3, MARÍA-DEL-MAR INDA4, ANNA LUCIA CONTE1, LAURA GÓMEZ-ESCOLAR5, HELENA MARTÍNEZ6, JOSÉ F. HORGA3, JOSÉ M. PALAZON5 and ANA M. PEIRÓ3,4 1Occupational Observatory, Miguel Hernández University (UMH) of Elche, 03202 Elche; 2CIBERehd, Carlos III Health Institute, 28029 Madrid; 3Clinical Pharmacology, General Hospital of Alicante; 4Neuropharmacology on Pain (NED) Research Group, ISABIAL-FISABIO, General Hospital of Alicante; 5Liver Unit, General Hospital of Alicante, 03010 Alicante; 6Clinical R&D Area, Bioiberica S.A., 08029 Barcelona, Spain Received June 12, 2017; Accepted September 28, 2017 DOI: 10.3892/mmr.2018.8820 Abstract. The present study was designed to investigate the Introduction functional status of β2 adrenoceptors (β2AR) in two models of chronic inflammatory disease: Liver cirrhosis (LC) and The role of the sympathetic nervous system (SNS) in inflam- osteoarthritis (OA). The β2AR gene contains three single mation is still not completely understood, although it is well nucleotide polymorphisms at amino acid positions 16, 27 and known that disturbed interaction between both contributes to 164. The aim of the present study was to investigate the poten- pathogenic chronic inflammatory diseases (1,2). Evidence for tial influence of lymphocyte β2AR receptor functionality and the possibility of such interaction have been reinforced since genotype in LC and OA patients. Blood samples from cirrhotic the discovery of the expression of beta-2-adrenergic receptor patients (n=52, hepatic venous pressure gradient 13±4 mmHg, (β2AR) on T and B lymphocytes, macrophages, natural killer CHILD 7±2 and MELD 11±4 scores), OA patients (n=30, 84% cells and neutrophils (3-6).
    [Show full text]
  • Discovery of Novel Imidazolines and Imidazoles As Selective TAAR1
    Discovery of Novel Imidazolines and Imidazoles as Selective TAAR1 Partial Agonists for the Treatment of Psychiatric Disorders Giuseppe Cecere, pRED, Discovery Chemistry F. Hoffmann-La Roche AG, Basel, Switzerland Biological Rationale Trace amines are known for four decades Trace Amines - phenylethylamine p- tyramine p- octopamine tryptamine (PEA) Biogenic Amines dopamine norepinephrine serotonin ( DA) (NE) (5-HT) • Structurally related to classical biogenic amine neurotransmitters (DA, NE, 5-HT) • Co-localised & released with biogenic amines in same cells and vesicles • Low concentrations in CNS, rapidly catabolized by monoamine oxidase (MAO) • Dysregulation linked to psychiatric disorders such as schizophrenia & 2 depression Trace Amines Metabolism 3 Biological Rationale Trace Amine-Associated Receptors (TAARs) p-Tyramine extracellular TAAR1 Discrete family of GPCR’s Subtypes TAAR1-TAAR9 known intracellular Gs Structural similarity with the rhodopsin and adrenergic receptor superfamily adenylate Activation of the TAAR1 cyclase receptor leads to cAMP elevation of intracellular cAMP levels • First discovered in 2001 (Borowsky & Bunzow); characterised and classified at Roche in 2004 • Trace amines are endogenous ligands of TAAR1 • TAAR1 is expressed throughout the limbic and monoaminergic system in the brain Borowsky, B. et al., PNAS 2001, 98, 8966; Bunzow, J. R. et al., Mol. Pharmacol. 2001, 60, 1181. Lindemann L, Hoener MC, Trends Pharmacol Sci 2005, 26, 274. 4 Biological Rationale Electrical activity of dopaminergic neurons + p-tyramine
    [Show full text]
  • G Protein-Coupled Receptors: What a Difference a ‘Partner’ Makes
    Int. J. Mol. Sci. 2014, 15, 1112-1142; doi:10.3390/ijms15011112 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Review G Protein-Coupled Receptors: What a Difference a ‘Partner’ Makes Benoît T. Roux 1 and Graeme S. Cottrell 2,* 1 Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK; E-Mail: [email protected] 2 Reading School of Pharmacy, University of Reading, Reading RG6 6UB, UK * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +44-118-378-7027; Fax: +44-118-378-4703. Received: 4 December 2013; in revised form: 20 December 2013 / Accepted: 8 January 2014 / Published: 16 January 2014 Abstract: G protein-coupled receptors (GPCRs) are important cell signaling mediators, involved in essential physiological processes. GPCRs respond to a wide variety of ligands from light to large macromolecules, including hormones and small peptides. Unfortunately, mutations and dysregulation of GPCRs that induce a loss of function or alter expression can lead to disorders that are sometimes lethal. Therefore, the expression, trafficking, signaling and desensitization of GPCRs must be tightly regulated by different cellular systems to prevent disease. Although there is substantial knowledge regarding the mechanisms that regulate the desensitization and down-regulation of GPCRs, less is known about the mechanisms that regulate the trafficking and cell-surface expression of newly synthesized GPCRs. More recently, there is accumulating evidence that suggests certain GPCRs are able to interact with specific proteins that can completely change their fate and function. These interactions add on another level of regulation and flexibility between different tissue/cell-types.
    [Show full text]
  • Structure, Function, and Pharmaceutical Ligands of 5-Hydroxytryptamine 2B Receptor
    pharmaceuticals Review Structure, Function, and Pharmaceutical Ligands of 5-Hydroxytryptamine 2B Receptor Qing Wang 1,2 , Yu Zhou 2 , Jianhui Huang 1 and Niu Huang 2,3,* 1 School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China; [email protected] (Q.W.); [email protected] (J.H.) 2 National Institute of Biological Sciences, No. 7 Science Park Road, Zhongguancun Life Science Park, Beijing 102206, China; [email protected] 3 Tsinghua Institute of Multidisciplinary Biomedical Research, Tsinghua University, Beijing 102206, China * Correspondence: [email protected]; Tel.: +86-10-80720645 Abstract: Since the first characterization of the 5-hydroxytryptamine 2B receptor (5-HT2BR) in 1992, significant progress has been made in 5-HT2BR research. Herein, we summarize the biological function, structure, and small-molecule pharmaceutical ligands of the 5-HT2BR. Emerging evidence has suggested that the 5-HT2BR is implicated in the regulation of the cardiovascular system, fibrosis disorders, cancer, the gastrointestinal (GI) tract, and the nervous system. Eight crystal complex structures of the 5-HT2BR bound with different ligands provided great insights into ligand recognition, activation mechanism, and biased signaling. Numerous 5-HT2BR antagonists have been discovered and developed, and several of them have advanced to clinical trials. It is expected that the novel 5-HT2BR antagonists with high potency and selectivity will lead to the development of first-in-class drugs in various therapeutic areas. Keywords: GPCR; 5-HT2BR; biased signaling; agonist; antagonist Citation: Wang, Q.; Zhou, Y.; Huang, J.; Huang, N. Structure, Function, and Pharmaceutical Ligands of 5-Hydroxytryptamine 2B Receptor. 1. Introduction Pharmaceuticals 2021, 14, 76.
    [Show full text]
  • Synergistic Action of 5-HT2A Antagonists and Selective Serotonin Reuptake Inhibitors in Neuropsychiatric Disorders
    Neuropsychopharmacology (2003) 28, 402–412 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Synergistic Action of 5-HT2A Antagonists and Selective Serotonin Reuptake Inhibitors in Neuropsychiatric Disorders ,1 2 3 2 Gerard J Marek* , Linda L Carpenter , Christopher J McDougle and Lawrence H Price 1Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA; 2Department of Psychiatry and Human, Brown Medical School, Mood 3 Disorders Program, Behavior, Butler Hospital, Providence, RI, USA; Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA Recently, the addition of drugs with prominent 5-HT2 receptor antagonist properties (risperidone, olanzapine, mirtazapine, and mianserin) to selective serotonin reuptake inhibitors (SSRIs) has been shown to enhance therapeutic responses in patients with major depression and treatment-refractory obsessive–compulsive disorder (OCD). These 5-HT antagonists may also be effective in 2 ameliorating some symptoms associated with autism and other pervasive developmental disorders (PDDs). At the doses used, these drugs would be expected to saturate 5-HT2A receptors. These findings suggest that the simultaneous blockade of 5-HT2A receptors and activation of an unknown constellation of other 5-HT receptors indirectly as a result of 5-HT uptake inhibition might have greater therapeutic efficacy than either action alone. Animal studies have suggested that activation of 5-HT1A and 5-HT2C receptors may counteract the effects of activating 5-HT2A receptors. Additional 5-HT receptors, such as the 5-HT1B/1D/5/7 receptors, may similarly counteract the effects of 5-HT receptor activation. These clinical and preclinical observations suggest that the combination of highly 2A selective 5-HT antagonists and SSRIs, as well as strategies to combine high-potency 5-HT receptor and 5-HT transporter blockade in 2A 2A a single compound, offer the potential for therapeutic advances in a number of neuropsychiatric disorders.
    [Show full text]
  • Alpha1-Adrenergic Receptor Activation Mimics Ischemic Postconditioning in Cardiac Myocytes
    ALPHA1-ADRENERGIC RECEPTOR ACTIVATION MIMICS ISCHEMIC POSTCONDITIONING IN CARDIAC MYOCYTES A dissertation submitted to Kent State University in cooperation with Northeast Ohio Medical University in partial fulfillment of the requirements for the degree of Doctor of Philosophy by Danielle M. Janota August, 2014 Dissertation written by Danielle M. Janota B.S., Ohio University, 2007 Ph.D., Kent State University, 2014 Approved by _____________________________, Chair, Doctoral Dissertation Committee June Yun, Ph.D. ______________________________, Member, Doctoral Dissertation Committee J. Gary Meszaros, Ph.D. ______________________________, Member, Doctoral Dissertation Committee Angelo L. DeLucia, Ph.D. ______________________________, Member, Doctoral Dissertation Committee Werner J. Geldenhuys, Ph.D. ______________________________, Graduate Faculty Representative Joel W. Hughes, Ph.D. Accepted by ______________________________, Director, School of Biomedical Sciences Eric M. Mintz, Ph.D. ______________________________, Dean, College of Arts and Sciences James L. Blank, Ph.D. ii TABLE OF CONTENTS List of Figures .................................................................................. v List of Tables ................................................................................. vii List of Abbreviations .....................................................................viii Acknowledgments........................................................................... xi Dedication ....................................................................................
    [Show full text]
  • The Essential Role of Β2-Adrenergic Receptor
    ORIGINAL ARTICLE Age-Related Impairment in Insulin Release The Essential Role of b2-Adrenergic Receptor Gaetano Santulli,1,2 Angela Lombardi,3,4 Daniela Sorriento,1 Antonio Anastasio,1 Carmine Del Giudice,1 Pietro Formisano,4 Francesco Béguinot,4 Bruno Trimarco,1 Claudia Miele,4 and Guido Iaccarino5 (5,6) as well as in humans (4,7,8). However, why insulin In this study, we investigated the significance of b2-adrenergic receptor (b2AR) in age-related impaired insulin secretion and secretion deteriorates with aging remains a moot point. glucose homeostasis. We characterized the metabolic phenotype The noradrenergic system provides fine-tuning to the 2/2 of b2AR-null C57Bl/6N mice (b2AR ) by performing in vivo and endocrine pancreas activity through the function of a- and ex vivo experiments. In vitro assays in cultured INS-1E b-cells b-adrenergic receptors (ARs) (9,10). The reciprocal regu- were carried out in order to clarify the mechanism by which lation exerted by insulin and the adrenergic system has fi 2/2 b2AR de ciency affects glucose metabolism. Adult b2AR mice been well documented through a large number of studies featured glucose intolerance, and pancreatic islets isolated from (11–13). More recent evidence shows that mice with si- these animals displayed impaired glucose-induced insulin release, accompanied by reduced expression of peroxisome proliferator– multaneous deletion of the three known genes encoding activated receptor (PPAR)g, pancreatic duodenal homeobox-1 the bARs (b1, b2, and b3) present a phenotype character- (PDX-1), and GLUT2. Adenovirus-mediated gene transfer of hu- ized by impaired glucose tolerance (14).
    [Show full text]
  • CHRONIC EFFECTS of a MONOAMINE OXIDASE-INHIBITING ANTIDEPRESSANT: DECREASES in FUNCTIONAL A-ADRENERGIC AUTORECEPTORSPRECEDETHEDE
    0270-6474/82/0211-1588$02.00/O The Journal of Neuroscience Copyright 0 Society for Neuroscience Vol. 2, No. 11, pp. 1588-1595 Printed in U.S.A. November 1982 CHRONIC EFFECTS OF A MONOAMINE OXIDASE-INHIBITING ANTIDEPRESSANT: DECREASES IN FUNCTIONAL a-ADRENERGIC AUTORECEPTORSPRECEDETHEDECREASEIN NOREPINEPHRINE-STIMULATED CYCLIC ADENOSINE 3’:WMONOPHOSPHATE SYSTEMS IN RAT BRAIN1 ROBERT M. COHEN,*,” RICHARD P. EBSTEIN,*,3 JOHN W. DALY,* AND DENNIS L. MURPHY* *Clinical Neuropharmacology Branch, National Institute of Mental Health and ‘Laboratory of Bioorganic Chemistry, National Institute of Arthritis, Metabolism and Digestive Diseases, Bethesda, Maryland 20205 Received November 2, 1981; Revised April 9, 1982; Accepted May 7, 1982 Abstract Various antidepressant drugs (monoamine oxidase inhibitors and tricyclics) enhance norepineph- rine availability and lead to adaptive changes in brain noradrenergic systems, namely, decreases in the number of p receptors and in the responsiveness of adenylate cyclase to norepinephrine stimulation. After 21 days of treatment with 1 mg/kg/day of clorgyline, an A-type-selective monoamine oxidase inhibitor, but not after 3 days, there is an increase in norepinephrine release from rat brain microsacs in response to 43 mM KC1 stimulation. Microsacs prepared from 21-day clorgyline-treated animals also show a marked decrease in the inhibition of norepinephrine release caused by the az-selective agonist clonidine. These functional changes in norepinephrine release mechanisms are accompanied by a 53% reduction in brainstem (~2receptor density as measured by [3H]clonidine binding. At the same time, despite findings of a decrease in p receptor number as determined by [3H]dihydroalprenolo1 binding data, no significant decrease in the responses of cyclic adenosine 3’:5’-monophosphate (cyclic AMP) systems to norepinephrine stimulation is observed.
    [Show full text]
  • Chapter 1 Introduction to Thyroid Hormone, Thyronamines, Monoamine
    Copyright 2008 by Aaron Nathan Snead ii Acknowledgments Portions of this work have been published elsewhere. Chapter 2 is adapted with the permission of the American Chemical Society from Snead, A.N., Santos, M.S., Seal, R.P., Edwards, R.H., and Scanlan T.S. (2007) Thyronamines inhibit plasma membrane and vesicular monoamine transport. ACS Chem Biol, 2(6), 390-8. Chapter 4 is adapted with permission of Elsevier Ltd. from Snead, A.N., Miyakawa, M., Tan, E.S., and Scanlan T.S. (2008) Trace amine-associated receptor 1 (TAAR1) is activated by amiodarone metabolites. Bioorg Med Chem Lett,18(22), 5920-2. Several Compounds tested for activity with rTAAR1,4 and 6 in Chapters 3 and 4 were synthesized by Motonori Miyakawa (Chapter 4, compounds 2, and 4-8) and Edwin S. Tan (Napthylethyamine, and Chapter 4, compounds 3 and 9). We also thank the Amara S. Lab for the donation of the hNET and hDAT DNA constructs, the Blakely R. Lab for the donation of the hSERT DNA construct, and the Grandy D. Lab for the donation of the r-hTAAR1 cell line. This work was supported by fellowship from the Ford Foundation and the NIH Research Supplement to Promote Diversity in Health-Related Research (A.S.), the PEW Latin American Fellowship (M.S.), the NIMH Postdoctoral Fellowship (R.S.), a grant from the NIMH (R.H.E.), and a grant from the National Institutes of Health (T.S.S.). iii Abstract Exploring the Non-Transcriptional Activity of Thyroid Hormone Derivatives This work is premised on the hypothesis that thyroid hormone may be a substrate for the aromatic L-amino acid decarboxylase (AADC) and that the resulting iodothyronamines would have significant structural and perhaps functional similarity with several biogenic amines including the classical monoamine neurotransmitters.
    [Show full text]
  • 5-HT2A Receptors in the Central Nervous System the Receptors
    The Receptors Bruno P. Guiard Giuseppe Di Giovanni Editors 5-HT2A Receptors in the Central Nervous System The Receptors Volume 32 Series Editor Giuseppe Di Giovanni Department of Physiology & Biochemistry Faculty of Medicine and Surgery University of Malta Msida, Malta The Receptors book Series, founded in the 1980’s, is a broad-based and well- respected series on all aspects of receptor neurophysiology. The series presents published volumes that comprehensively review neural receptors for a specific hormone or neurotransmitter by invited leading specialists. Particular attention is paid to in-depth studies of receptors’ role in health and neuropathological processes. Recent volumes in the series cover chemical, physical, modeling, biological, pharmacological, anatomical aspects and drug discovery regarding different receptors. All books in this series have, with a rigorous editing, a strong reference value and provide essential up-to-date resources for neuroscience researchers, lecturers, students and pharmaceutical research. More information about this series at http://www.springer.com/series/7668 Bruno P. Guiard • Giuseppe Di Giovanni Editors 5-HT2A Receptors in the Central Nervous System Editors Bruno P. Guiard Giuseppe Di Giovanni Faculté de Pharmacie Department of Physiology Université Paris Sud and Biochemistry Université Paris-Saclay University of Malta Chatenay-Malabry, France Msida MSD, Malta Centre de Recherches sur la Cognition Animale (CRCA) Centre de Biologie Intégrative (CBI) Université de Toulouse; CNRS, UPS Toulouse, France The Receptors ISBN 978-3-319-70472-2 ISBN 978-3-319-70474-6 (eBook) https://doi.org/10.1007/978-3-319-70474-6 Library of Congress Control Number: 2017964095 © Springer International Publishing AG 2018 This work is subject to copyright.
    [Show full text]
  • Classification and Signaling Characteristics of 5-HT Receptors
    Classification and Signaling Characteristics of 5-HT Receptors: Towards the Concept of 5-HT Receptosomes Philippe Marin, Carine Becamel, Séverine Chaumont-Dubel, Franck Vandermoere, Joël Bockaert, Sylvie Claeysen To cite this version: Philippe Marin, Carine Becamel, Séverine Chaumont-Dubel, Franck Vandermoere, Joël Bockaert, et al.. Classification and Signaling Characteristics of 5-HT Receptors: Towards the Concept of5-HT Receptosomes. Handbook of Behavioral Neuroscience, 31 (Chapter 5), pp.91-120, 2020, Handbook of Behavioral Neurobiology of Serotonin, 10.1016/B978-0-444-64125-0.00005-0. hal-02491823 HAL Id: hal-02491823 https://hal.archives-ouvertes.fr/hal-02491823 Submitted on 26 Feb 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Classification and Signaling Characteristics of 5-HT Receptors: Towards the Concept of 5-HT Receptosomes Philippe Marin, Carine Bécamel, Séverine Chaumont-Dubel, Franck Vandermoere, Joël Bockaert, Sylvie Claeysen IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, France. Corresponding author: Dr Philippe Marin, Institut de Génomique Fonctionnelle, 141 rue de la Cardonille, 34094 Montpellier Cedex 5, France. Email: [email protected] Phone: +33 434 35 92 42. Other contact information: Dr Carine Bécamel, Institut de Génomique Fonctionnelle, 141 rue de la Cardonille, 34094 Montpellier Cedex 5, France.
    [Show full text]